DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial
DalCor Pharmaceuticals today announced it has randomzied the first patient in the Phase 3 “dal-GenE” clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene. The worldwide clinical trial will be led by the Montreal Heart Institute.
DalCor Pharmaceuticals Completes $150 Million Financing
DalCor Pharmaceuticals today announced the completion of $150 million in private financing to continue development of dalcetrapib in a genetically distinct population of patients with cardiovascular disease.
Roche to Develop Companion Diagnostic Test for Acute Coronary Syndrome
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has entered into an agreement to develop a companion diagnostic (CDx) test for dalcetrapib, a therapeutic from DalCor Pharmaceuticals (DalCor), which will target patients with a specific genotype who have experienced a recent Acute Coronary Syndrome (ACS) event.
DalCor Pharmaceuticals Licenses a Late-Stage Investigational Cardiovascular Drug Following Major Discovery by Montreal Heart Institute (MHI) Scientists
DalCor Pharmaceuticals Canada Inc. (DalCor) and the Montreal Heart Institute (MHI) announced today a collaboration in principle to conduct an international Phase III clinical trial which could result in a major clinical advance in cardiovascular personalised medicine.
